MiMedx Group, Inc. (MDXG) shares are up almost 3% pre-bell after the manufacturer of regenerative biomaterials and bioimplants processed from human amniotic membrane, said directors have approved a $10 million share buyback.
The program runs through to December 2014.
“The announcement of the stock repurchase program reflects the Board’s and management’s confidence in the long-term growth prospects of the company’s business and favorable outlook for earnings and cash flows,” said Parker H. Petit, Chairman and CEO.
The shares recently traded at $5.57 with a 52-week range of $1.81 – $8.80.
Latest posts by Nathan Fortin (see all)
- The End of Life Option Act Already Used by 111 People - Jun 28, 2017
- Senate Decided to Kill Rule that Promotes Retirement Plans - Apr 1, 2017
- BlackRock Is Turning to Robots for Improved Stocks - Mar 30, 2017